Pure Global
NCT05600127

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer: the CHASIT Study
Erasmus Medical Center·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Avelumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Erasmus Medical Center
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2022
End date
Dec 01, 2026
Enrollment
64 participants
Primary outcome

Pathological complete response rate

Summary

Patients with locally advanced or clinically node positive urothelial carcinoma treated with
 chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05600127
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05600127 through Pure Global AI's free database. This Phase 2 trial is sponsored by Erasmus Medical Center and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.